Peak Retirement Planning Inc. Makes New $837,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Peak Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 9,066 shares of the biopharmaceutical company's stock, valued at approximately $837,000.

A number of other hedge funds also recently bought and sold shares of the company. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $28,000. Crews Bank & Trust purchased a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $31,000. Stephens Consulting LLC lifted its position in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares in the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC lifted its position in shares of Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 216 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total transaction of $266,000.00. Following the sale, the chief financial officer now owns 168,174 shares in the company, valued at $17,893,713.60. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the sale, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. This represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,929 shares of company stock worth $5,644,780. Insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded down $0.65 during midday trading on Wednesday, hitting $108.44. The company had a trading volume of 4,591,464 shares, compared to its average volume of 7,714,363. The business's 50 day simple moving average is $105.33 and its two-hundred day simple moving average is $100.52. The stock has a market cap of $134.89 billion, a PE ratio of 293.08, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the company posted ($1.32) earnings per share. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.91%. Gilead Sciences's payout ratio is 66.53%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Piper Sandler increased their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Cantor Fitzgerald assumed coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Bank of America increased their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Finally, Oppenheimer dropped their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.